乳腺癌雌激素受体孕激素受体和C-erbB-2癌基因蛋白表达的临床意义  

Expression of ER, PR and C-erbB-2 in breast cancer and their clinical significance

作　　者：朱李华[1] 党小雨[1] 刘蓉[1] 

机构地区：[1]西安市中心医院病理科,710003

出　　处：《肿瘤研究与临床》2005年第6期375-377,共3页Cancer Research and Clinic

摘　　要：目的研究乳腺癌中雌、孕激素受体(ER,PR)与C,erbB-2癌基因的表达情况及临床意义。方法应用免疫组化S.P法,对82例原发性乳腺癌组织进行了ER,PR和C/erbB02检测,并进行统计学分析。结果ER,PR和C1erbB22的表达率分别为54.9%,40.2%,47.6%。ER的表达与C3erbB42的表达呈显著负相关(P<0.01)。C5erbB62的表达与肿瘤体积呈显著正相关(P<0.01),与年龄、组织学类型和淋巴结转移无明显相关性(P>0.05)。结论ER,PR的阳性表达是乳腺癌预后良好的指标,C7erbB82是乳腺癌预后不良的指标。ER,PR和C9erbB:2的测定对乳腺癌的诊断、治疗和预后判断具有重要的指导意义。Objective To investigate the expression and clinical significance of ER,PR and C-erbB-2 in breast cancer. Methods 82 cases of primary breast cancer were examined for ER, PR and C-erbB-2 by immunohistochemical S-P methods, Results The expressions of ER, PR and C-erbB-2 were 54.9 %, 40.2 %, 47.6 % respectively. There was a negative correlation between ER and C-erbB-2（P 〈0.01）. The expressions of C-erbB-2 was significantly correlated with tumor size （P 〈0.01）. Conclusions For breast cancer, C-erbB-2 positive might serve as an indicator for poor prognosis, but ER and PR positive expression were indicators for a good prognosis.

关 键 词：乳腺癌 雌激素受体 孕激素受体 C-ERBB-2癌基因 

分 类 号：R737.9[医药卫生—肿瘤]